← Back to Screener
Celcuity Inc. Common Stock (CELC)
Price$122.96
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)25.43%
Price vs S&P 500 (4W)0.78%
VGM Score74.06
Market Capitalization$6.48B
All Metrics
Book Value / Share (Quarterly)$1.11
P/TBV (Annual)2.49x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.58
Price vs S&P 500 (YTD)22.29%
EPS (TTM)$-3.90
10-Day Avg Trading Volume0.87M
EPS Excl Extra (TTM)$-3.90
EPS (Annual)$-3.79
ROI (Annual)-41.91%
Cash / Share (Quarterly)$8.01
ROA (Last FY)-37.95%
EBITD / Share (TTM)$-3.76
ROE (5Y Avg)-78.33%
Cash Flow / Share (Annual)$-3.18
P/B Ratio121.07x
P/B Ratio (Quarterly)103.08x
Net Income / Employee (Annual)$-1,142,200
Net Interest Coverage (TTM)-35.50x
ROA (TTM)-50.22%
EPS Incl Extra (Annual)$-3.79
Current Ratio (Annual)10.55x
Quick Ratio (Quarterly)11.85x
3-Month Avg Trading Volume0.86M
52-Week Price Return1128.10%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.15
52-Week High$151.02
EPS Excl Extra (Annual)$-3.79
CapEx CAGR (5Y)22.57%
Tangible BV CAGR (5Y)33.63%
26-Week Price Return41.36%
Quick Ratio (Annual)10.12x
13-Week Price Return19.58%
Total Debt / Equity (Annual)3.20x
Current Ratio (Quarterly)12.31x
Enterprise Value$6.66B
Book Value / Share Growth (5Y)12.91%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.15
3-Month Return Std Dev65.07%
Net Income / Employee (TTM)$-1,244,400
ROE (Last FY)-176.06%
Net Interest Coverage (Annual)-29.52x
EPS Basic Excl Extra (Annual)$-3.79
Total Debt / Equity (Quarterly)6.04x
EPS Incl Extra (TTM)$-3.90
ROI (TTM)-55.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.17
Price vs S&P 500 (52W)1099.89%
Year-to-Date Return33.23%
5-Day Price Return-3.87%
EPS Normalized (Annual)$-3.79
ROA (5Y Avg)-34.87%
Month-to-Date Return9.50%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$-3.68
LT Debt / Equity (Annual)3.20x
ROI (5Y Avg)-37.97%
LT Debt / Equity (Quarterly)6.04x
EPS Basic Excl Extra (TTM)$-3.90
P/TBV (Quarterly)3.58x
P/B Ratio (Annual)45.90x
Book Value / Share (Annual)$2.08
Price vs S&P 500 (13W)9.84%
Beta0.12x
Revenue / Share (TTM)$0.00
ROE (TTM)-244.61%
52-Week Low$10.50
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.97est. -1.07
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.29
4.28
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| VCYTVeracyte, Inc. | D | A | B | $48.18 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
| FTREFortrea Holdings Inc. Common Stock | B | F | A | $15.76 |
About
Celcuity is a clinical-stage oncology biotechnology company developing gedatolisib, a dual PI3K/mTOR inhibitor with a differentiated mechanism of action compared to existing therapies. The company's lead program is in Phase 3 development (VIKTORIA-1), evaluating gedatolisib combined with fulvestrant with or without palbociclib for hormone receptor-positive, HER2-negative advanced breast cancer.